Merck & Company Inc. (MRK)
NYSE: MRKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MRK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $352.29B
- P/E (TTM)
- 113.33
- Forward P/E
- 15.08
- EPS (TTM)
- $1.26
- Dividend yield
- 2.33% ($3.32)
- Ex-dividend date
- Sep 15, 2026
- 52-week range
- 82.01 – 156.92
- Day range
- 141.52 – 144.15
- Volume / Avg
- 6.35M / 9.82M
- Beta
- —
- Shares outstanding
- 2.47B
- Next earnings
- Oct 29, 2026
52-week range
MRK stock today
On Oct 7, MRK ended the session at $142.79, adding $0.85 (0.60%), versus the S&P 500's 0.22% decline. At this level, MRK sits near the top of its 52-week range of $82.01 to $156.92: 9.0% below the high, set on Aug 25, 2026 and 74.1% above the low. MRK is up 35.7% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 63.0%.
At 113.3x trailing earnings, Merck trades above the peer-group median of 26.7x. Its forward P/E of 15.1x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Merck's next earnings report is expected on Oct 29, 2026. Merck pays an annual dividend of $3.32 per share, a 2.33% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Merck
Company profileMerck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert M. Davis J.D.
- Headquarters
- Rahway, NJ
- Employees
- 73,000
- Website
- merck.com
Financial highlights
Full financialsIn fiscal 2025, Merck generated $65.01 billion in revenue, up 1.3% from fiscal 2024, its 6th consecutive year of revenue growth. Net income was $18.25 billion (+6.6% year over year), for a net margin of 28.1% versus a median of 24.5% in the prior 5 years. Gross margin was 74.8% (down from 76.3%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Growth | +1.31% | +6.74% | +1.40% | +21.72% | +17.31% |
| Net income | $18.25B | $17.12B | $365.00M | $14.52B | $13.05B |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
Analyst forecast
ForecastConsensus (27 analysts)
buy
Avg. price target
$156.28+9.45%
- Strong buy 5
- Buy 14
- Hold 8
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $2.25
- Last reported (Q2 2026)
- Aug 7, 2026
- EPS actual vs est.
- $-0.54 vs —
Dividends
Dividend history- Annual dividend
- $3.32
- Dividend yield
- 2.33%
- Last payment
- $0.85
- Ex-dividend date
- Sep 15, 2026
MRK news
All MRK news- Merck’s injectable Keytruda barred in Europe as Halozyme wins injunctionSeeking Alpha
- New York Declares Statewide Disaster Emergency As Measles Cases Continue To RiseNasdaq
- Merck (MRK) Beats Stock Market Upswing: What Investors Need to KnowNasdaq
- Invesco MSCI USA ETF Experiences Big OutflowNasdaqPBUS, MRK, KO, MS
- Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?NasdaqMRK, AZN, MRNA
- Dow Movers: MRK, HONIVNasdaqMRK, NKE, MSFT
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowNasdaqPGEN, MRK, INO
- 3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury NoteNasdaqPFE, LLY, ABBV, MRK
Merck peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVSNovartis AG | 143.28 | +1.77% | $272.33B | vs MRK |
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs MRK |
| ABBVAbbVie Inc. | 271.36 | +1.75% | $479.52B | vs MRK |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs MRK |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs MRK |
| PFEPfizer Inc. | 28.00 | +1.82% | $159.59B | vs MRK |
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs MRK |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs MRK |
Indexes, lists and sector
Merck stock FAQ
What is Merck's stock price today?
MRK last traded at $142.79 as of Oct 7, 4:00 PM EDT, up 0.60% on the day. Prices are delayed at least 15 minutes.
Does Merck pay a dividend?
Yes. Merck pays $3.32 per share annually, a 2.33% yield. The most recent dividend of $0.85 had an ex-dividend date of Sep 15, 2026.
When is Merck's next earnings date?
Merck is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $2.25.
What is MRK's P/E ratio?
MRK trades at a trailing P/E ratio of 113.33 and a forward P/E of 15.08, compared with a median of 26.7 for its closest peers.
Is Merck in the S&P 500?
Yes. Merck (MRK) is a constituent of the S&P 500 index.
Who is Merck's CEO?
Mr. Robert M. Davis J.D. is the chief executive officer of Merck & Company Inc., which has about 73,000 employees.
Has MRK ever split its stock?
Yes. The most recent MRK stock split was a 1048-for-1000 split on Jun 3, 2021, one of 6 splits on record.